Literature DB >> 25497786

Secular trends in the incidence of primary hyperparathyroidism over five decades (1965-2010).

Marcio L Griebeler1, Ann E Kearns1, Euijung Ryu2, Matthew A Hathcock2, L Joseph Melton3, Robert A Wermers4.   

Abstract

Introduction of automated serum calcium measurements in the 1970s resulted in a sharp rise in primary hyperparathyroidism (PHPT) incidence. However, recent investigations suggest a significant rise in PHPT incidence for unclear reasons. Our objective was to update our population-based secular trends in PHPT incidence, to determine if there has been a significant rise in PHPT incidence as suggested by others, and, if possible, to identify changes in clinical practice that might be responsible. Rochester, Minnesota, residents who met the criteria for PHPT from 2002 through 2010 were identified through the medical records-linkage system of the Rochester Epidemiology Project and added to the historical cohort beginning in 1965. Incidence rates were adjusted to the 2010 US white population. Altogether, 1142 Rochester residents have been diagnosed with PHPT since 1965, including 341 in 2002-2010. Over time, two periods of increased PHPT incidence occurred, one beginning in 1974 (121.7 per 100,000 person-years) and a second peak (86.2 per 100,000 person-years) starting in 1998. The median age of PHPT subjects has increased significantly from 55 years in 1985-1997 to 60 years of age in 1998-2010 and more patients (36%) had a parathyroidectomy in 1998-2010. Although serum calcium measurement has declined since 1996, there was a progressive increase in parathyroid hormone testing between 1994 and 2008. There was also a rise in orders for bone mineral density measurements in women since 1998, which peaked in 2003-2004. A second sharp rise in PHPT incidence occurred in our community in 1998, simultaneously with the introduction of national osteoporosis screening guidelines, Medicare coverage for bone density measurement, and new medications for the treatment of osteoporosis. Case ascertainment bias from targeted PHPT screening in patients being evaluated for osteoporosis is the most likely explanation.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Epidemiology; Hypercalcemia; Incidence; Osteoporosis; Primary hyperparathyroidism

Mesh:

Year:  2014        PMID: 25497786      PMCID: PMC4445941          DOI: 10.1016/j.bone.2014.12.003

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  33 in total

Review 1.  Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century.

Authors:  John P Bilezikian; John T Potts; Ghada El-Hajj Fuleihan; Michael Kleerekoper; Robert Neer; Munro Peacock; Jonas Rastad; Shonni J Silverberg; Robert Udelsman; Samuel A Wells
Journal:  J Bone Miner Res       Date:  2002-11       Impact factor: 6.741

Review 2.  The epidemiology of primary hyperparathyroidism in North America.

Authors:  L Joseph Melton
Journal:  J Bone Miner Res       Date:  2002-11       Impact factor: 6.741

3.  Primary hyperparathyroidism detected in a health screening. The Trømsø study.

Authors:  R Jorde; K H Bønaa; J Sundsfjord
Journal:  J Clin Epidemiol       Date:  2000-11       Impact factor: 6.437

4.  National trends in osteoporosis visits and osteoporosis treatment, 1988-2003.

Authors:  Randall S Stafford; Rebecca L Drieling; Adam L Hersh
Journal:  Arch Intern Med       Date:  2004-07-26

5.  Advances in diagnostic practices affect thyroid cancer incidence in France.

Authors:  L Leenhardt; M O Bernier; M H Boin-Pineau; B Conte Devolx; R Maréchaud; P Niccoli-Sire; M Nocaudie; J Orgiazzi; M Schlumberger; J L Wémeau; L Chérie-Challine; F De Vathaire
Journal:  Eur J Endocrinol       Date:  2004-02       Impact factor: 6.664

6.  Primary hyperparathyroidism. Incidence, morbidity, and potential economic impact in a community.

Authors:  H Heath; S F Hodgson; M A Kennedy
Journal:  N Engl J Med       Date:  1980-01-24       Impact factor: 91.245

7.  Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results.

Authors:  Jennifer S Haas; Celia P Kaplan; Eric P Gerstenberger; Karla Kerlikowske
Journal:  Ann Intern Med       Date:  2004-02-03       Impact factor: 25.391

8.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

9.  National use of postmenopausal hormone therapy: annual trends and response to recent evidence.

Authors:  Adam L Hersh; Marcia L Stefanick; Randall S Stafford
Journal:  JAMA       Date:  2004-01-07       Impact factor: 56.272

10.  Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women.

Authors:  Cara Tannenbaum; Julie Clark; Kevin Schwartzman; Sylvan Wallenstein; Robert Lapinski; Diane Meier; Marjorie Luckey
Journal:  J Clin Endocrinol Metab       Date:  2002-10       Impact factor: 5.958

View more
  35 in total

1.  Thiazide-Associated Hypercalcemia: Incidence and Association With Primary Hyperparathyroidism Over Two Decades.

Authors:  Marcio L Griebeler; Ann E Kearns; Euijung Ryu; Prabin Thapa; Matthew A Hathcock; L Joseph Melton; Robert A Wermers
Journal:  J Clin Endocrinol Metab       Date:  2016-01-11       Impact factor: 5.958

Review 2.  Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment.

Authors:  Peter J Tebben; Ravinder J Singh; Rajiv Kumar
Journal:  Endocr Rev       Date:  2016-09-02       Impact factor: 19.871

Review 3.  Familial hypocalciuric hypercalcemia and related disorders.

Authors:  Janet Y Lee; Dolores M Shoback
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2018-05-26       Impact factor: 4.690

4.  Epidemiology and prognosis of parathyroid carcinoma: real-world data using nationwide cohort.

Authors:  Sung Hye Kong; Jung Hee Kim; Man Young Park; Sang Wan Kim; Chan Soo Shin
Journal:  J Cancer Res Clin Oncol       Date:  2021-03-18       Impact factor: 4.553

Review 5.  Management of Primary Hyperparathyroidism.

Authors:  Murad Lala
Journal:  Indian J Surg Oncol       Date:  2021-04-27

Review 6.  The Causes of Hypo- and Hyperphosphatemia in Humans.

Authors:  Eugénie Koumakis; Catherine Cormier; Christian Roux; Karine Briot
Journal:  Calcif Tissue Int       Date:  2020-04-13       Impact factor: 4.333

Review 7.  Comparative efficacy of parathyroidectomy and active surveillance in patients with mild primary hyperparathyroidism: a systematic review and meta-analysis.

Authors:  N Singh Ospina; S Maraka; R Rodriguez-Gutierrez; A E Espinosa de Ycaza; S Jasim; M Gionfriddo; A Castaneda-Guarderas; J P Brito; A Al Nofal; P Erwin; R Wermers; V Montori
Journal:  Osteoporos Int       Date:  2016-08-25       Impact factor: 4.507

Review 8.  Outcomes of Parathyroidectomy in Patients with Primary Hyperparathyroidism: A Systematic Review and Meta-analysis.

Authors:  Naykky M Singh Ospina; Rene Rodriguez-Gutierrez; Spyridoula Maraka; Ana E Espinosa de Ycaza; Sina Jasim; Ana Castaneda-Guarderas; Michael R Gionfriddo; Alaa Al Nofal; Juan P Brito; Patricia Erwin; Melanie Richards; Robert Wermers; Victor M Montori
Journal:  World J Surg       Date:  2016-10       Impact factor: 3.352

Review 9.  Primary hyperparathyroidism.

Authors:  Marcella D Walker; Shonni J Silverberg
Journal:  Nat Rev Endocrinol       Date:  2017-09-08       Impact factor: 43.330

10.  Selective Parathyroid Hormone Venous Sampling in Patients with Persistent or Recurrent Primary Hyperparathyroidism and Negative, Equivocal or Discordant Noninvasive Imaging.

Authors:  Philip Y Sun; Scott M Thompson; James C Andrews; Robert A Wermers; Travis J McKenzie; Melanie L Richards; David R Farley; Geoffrey B Thompson
Journal:  World J Surg       Date:  2016-12       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.